U.S.-based Gilead Sciences has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.
Lifestyle - NY Daily News, New York Daily: Living
Tue, 09/16/2014 - 10:19am
U.S.-based Gilead Sciences has reached a deal with several generic drugmakers to produce cheaper versions of its popular, expensive hepatitis C drug Sovaldi for use in developing countries.